Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.150
-0.130 (-3.04%)
At close: Apr 28, 2026, 4:00 PM EDT
4.180
+0.030 (0.72%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Arbutus Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 14.08 | 6.17 | 18.14 | 39.02 | 10.99 | Upgrade
|
| Revenue Growth (YoY) | 128.21% | -65.98% | -53.51% | 255.11% | 58.92% | Upgrade
|
| Cost of Revenue | 25.24 | 54.04 | 73.7 | 84.41 | 65.5 | Upgrade
|
| Gross Profit | -11.16 | -47.87 | -55.56 | -45.39 | -54.51 | Upgrade
|
| Selling, General & Admin | 15.89 | 22.11 | 22.48 | 17.83 | 17.14 | Upgrade
|
| Operating Expenses | 15.89 | 22.11 | 22.48 | 17.83 | 17.14 | Upgrade
|
| Operating Income | -27.05 | -69.97 | -78.03 | -63.22 | -71.65 | Upgrade
|
| Interest Expense | -0.1 | -0.14 | -0.46 | -1.73 | -2.86 | Upgrade
|
| Interest & Investment Income | 4.07 | 6.59 | 5.69 | 2.19 | 0.13 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | -0.05 | 0.03 | -0.02 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -23.07 | -63.58 | -72.78 | -62.78 | -74.38 | Upgrade
|
| Merger & Restructuring Charges | -12.94 | -3.72 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.67 | - | - | - | - | Upgrade
|
| Other Unusual Items | 1.83 | -2.63 | -0.07 | -2.23 | -1.87 | Upgrade
|
| Pretax Income | -33.5 | -69.92 | -72.85 | -65.01 | -76.25 | Upgrade
|
| Income Tax Expense | - | - | - | 4.44 | - | Upgrade
|
| Net Income | -33.5 | -69.92 | -72.85 | -69.46 | -76.25 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 12.14 | Upgrade
|
| Net Income to Common | -33.5 | -69.92 | -72.85 | -69.46 | -88.39 | Upgrade
|
| Shares Outstanding (Basic) | 192 | 186 | 166 | 151 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 192 | 186 | 166 | 151 | 106 | Upgrade
|
| Shares Change (YoY) | 3.23% | 11.84% | 9.95% | 42.07% | 40.10% | Upgrade
|
| EPS (Basic) | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 | Upgrade
|
| EPS (Diluted) | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 | Upgrade
|
| Free Cash Flow | -39.64 | -65.03 | -86.94 | -35.87 | -68.34 | Upgrade
|
| Free Cash Flow Per Share | -0.21 | -0.35 | -0.52 | -0.24 | -0.64 | Upgrade
|
| Gross Margin | -79.23% | - | - | -116.32% | - | Upgrade
|
| Operating Margin | -192.08% | -1133.92% | -430.15% | -162.03% | -652.07% | Upgrade
|
| Profit Margin | -237.88% | -1133.04% | -401.57% | -178.01% | -804.39% | Upgrade
|
| Free Cash Flow Margin | -281.45% | -1053.83% | -479.27% | -91.92% | -621.96% | Upgrade
|
| EBITDA | -26.69 | -68.59 | -76.63 | -61.8 | -69.9 | Upgrade
|
| EBITDA Margin | -189.50% | - | - | -158.37% | - | Upgrade
|
| D&A For EBITDA | 0.36 | 1.38 | 1.4 | 1.43 | 1.75 | Upgrade
|
| EBIT | -27.05 | -69.97 | -78.03 | -63.22 | -71.65 | Upgrade
|
| EBIT Margin | -192.08% | - | - | -162.03% | - | Upgrade
|
| Revenue as Reported | 14.08 | 6.17 | 18.14 | 39.02 | 10.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.